Frequently asked questions
The global breast lesion localization methods market was valued at USD 0.2 Billion in 2022.
The breast lesion localization methods market is expected to grow at a CAGR of 5.0% between 2023 and 2030, reaching USD 0.3 Billion in 2030.
Mammography-guided localization is the leading segment by type of technique, holding over 20% share in value in 2022.
Biopsy governs the global demand for breast lesion localization methods, holding a massive share of over 30% in 2022.
The hospitals segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the breast lesion localization methods industry, with an over one-third share in 2022.
The top players include C.R. Bard, Inc. (a subsidiary of Becton, Dickinson, and Company), Cook Medical LLC, STERYLAB S.r.l., Tsunami Medical S.r.l., Argon Medical Devices, Inc., and CP Medical, Inc.
The major market drivers are the increasing prevalence of breast cancer, technological advancements in imaging techniques, and growing awareness about breast cancer screening and early detection.
The major market restraints include high costs associated with advanced imaging technologies and localization devices and limited accessibility and adoption in resource-constrained healthcare settings.
Integration of artificial intelligence (AI) and machine learning algorithms, development of minimally invasive and non-invasive localization techniques, and adoption of advanced imaging technologies and equipment.